SDIX, a provider of immuno-solutions to the pharmaceutical, biotechnology and diagnostics markets, has reported revenues of $7.47m for the third quarter ended 30 September 2010, compared to $7.2m for the same period in 2009.
SDIX has posted a net loss of $29,000 for the third quarter 2010, or $0 loss per diluted share, compared to net loss of $291,000 or $0.01 loss per diluted share, for the comparable period in 2009.
Operating loss was $20,000 compared to $281,000 for the comparable period in 2009.
SDIX has posted a revenue of $20.96m, for the nine months ended 30 September 2010, compared to $20.95m for the year ago period.
For the nine months ended 30 September 2010, SDIX has posted a net loss of $703,000, or $0.03 loss per diluted share, compared to net loss of $1.59m, or $0.08 loss per diluted share, for the year ago period.
Operating loss was $668,000, compared to $1.57m for the year ago period.
SDIX president and CEO Francis DiNuzzo said that they continue to see results from their strategic focus on the Life Science and Food Safety markets, with continued quarter over quarter revenue growth in their overall business.
“This improving growth, combined with the efficiency of our business operations, allowed SDIX to operate near break even this quarter,” DiNuzzo said.
“Consistent with our previous comments, the Life Science business results often vary quarter to quarter due to buying patterns, especially in the in-vitro diagnostic (IVD) market. We expect our Life Science business, including the IVD business, to improve in the fourth quarter as compared to the fourth quarter of 2009 based on current activities within that customer base.”